• Vaccine Name: rDNA-expressed S protein + alum vaccine
• Target Pathogen: SARS-CoV
• Target Disease: Severe Acute Respiratory Syndrome (SARS)
• Type: DNA vaccine
• Status: Research
• Host Species for Licensed Use: None
• Host Species as Laboratory Animal Model: mouse
• Antigen: ectodomain of the S protein(Tseng et al., 2012)
• Immunization Route: intranasal immunization
• Description: rDNA-expressed ectodomain of the S protein + alum vaccine (Tseng et al., 2012)

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: Each mouse received 100 µl injection of the vaccine intramuscularly on days 0 and 28. This was done at 2 µg, 1 µg, 0.5 µg, 0.5 µg of the vaccine per injection (Tseng et al., 2012)
• Immune Response: Increased titer of neutralizing antibodies and reduced viral titer, higher titer of neutralizing antibodies without adjuvant (Tseng et al., 2012)
• Side Effects: eosinophil infiltration in the lung lesions after challenge, lessened compared to without adjuvant (Tseng et al., 2012)
• Challenge Protocol: On day 56 after first vaccination, each mice was challenged challenged with 10^6TCID50/60 µl of SARS-CoV intranasally (IN) and euthanized on day 58 (Tseng et al., 2012)
• Efficacy: protected(Tseng et al., 2012)